The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from J485 treatment, as compared to...
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
The biotech obtained dovitinib—a small-molecule, pan-tyrosine kinase inhibitor—in 2018 from Swiss drug giant Novartis, centering its pipeline around the drug. Allarity hoped dovitinib would be approved for adults with metastatic renal cell carcinoma (mRCC) in 2022, even signing on to a manufacturing agreement with CDMO giant Lonza that would support potential commercialization.
Allarity Therapeutics, a clinical-stage precision medicine company, has announced its collaboration with biopharma partner Lonza to manufacture dovitinib. Dovitinib targets metastatic renal cell carcinoma (RCC) with other potential uses in liver cancer, breast cancer and various solid tumours.
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced validation results for its Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which will be included in a poster presentation at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress taking place from September 16 until September 21, 2021.
Hørsholm, Denmark (5 July 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has provided a positive administrative acceptance and review notification for the Company's PMA application for its Dovitinib-DRP®, the Company’s validated companion diagnostic for the drug dovitinib. Dovitinib is a small molecule, pan-tyrosine kinase inhibitor in-licensed from Novartis, and is Allarity’s most advanced clinical asset.
Hørsholm, Denmark and Boston, MA, U.S.A. (14 June 2021) – Allarity Therapeutics A/S (“Allarity”) and Oncoheroes Biosciences, Inc. (“Oncoheroes”) today announced that they have entered into binding term sheets for agreements under which Oncoheroes will acquire certain rights to dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor, and assume responsibility for their further clinical development in pediatric cancer.
Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for dovitinib, a pan-tyrosine kinase inhibitor (TKI) that is one of Allarity’s priority programs.
Hoersholm, Denmark (8 June 2020) – Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) announced today that it has acquired the remaining 37% ownership in its priority Dovitinib program from investor Sass & Larsen ApS. As a result of the transaction, the Company now has full control of its most advanced pipeline program.
Hoersholm, Denmark and Cambridge, MA, US, February 7, 2019 – Oncology Venture A/S (“OV” or “the Company”) today provides a clinical update on its precision drug projects. Oncology Venture has finalized the data mining process for dovitinib and its companion DRP® in renal cancer and endometrial cancer. This datamining has given a precision improvement, and there is now, in both cases, an even stronger identification by the DRP® of the responders based on patient biopsy and gene expression data. The DRP gives dovitinib with a strong competitive edge.